67 citations
,
October 2005 in “Annals of Oncology” This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.
January 2025 in “Biomedicines” In this study, female rats given high doses of testosterone showed decreased endometrial thickness and lower mRNA levels of components in the LIF signalling pathway, indicating that excessive testosterone may negatively impact endometrial receptivity and potentially affect fertility.
March 2024 in “The journal of sexual medicine” This case study observed that in four middle-aged men with ejaculation disorders, therapy with human chorionic gonadotropin (hCG) alone or combined with recombinant follicle-stimulating hormone (rFSH) improved sexual desire, semen volume, and various other symptoms, although some experienced elevated estradiol levels and hair loss.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.